InflaRx to discontinue vilobelimab indication following IDMC recommendation

InflaRx (IFRX) announced that the Independent Data Monitoring Committee conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum, recommended that the trial be stopped due to futility. This recommendation was based on data analysis of the first 30 patients enrolled in the study, with no unexpected adverse events noted by the IDMC. InflaRx as the study sponsor remains blinded to the study results. InflaRx intends to discontinue further development of vilobelimab in the PG indication and to prioritize its resources on INF904, with Phase 2a data readouts in chronic spontaneous urticaria and hidradenitis suppurativa anticipated this summer. The company is also considering additional cost savings and redirection of resources toward the goal of extending the company’s existing cash runway.